Satya Pharma Innovations
Flagship program - RAD51:BRCA2 Disruptor
Potential foundational drug across all high replication stress tumors
RAD51 is the central recombinase involved in homologous-mediated DNA double strand break repair, downstream of PARP, ATR, ATM, and CHK1/2. The centrality and functionality of RAD51 in the DDR pathway confers upon it a broad role in various replication stress-induced cancers. Unlike precision oncology drugs, targeted RAD51:BRCA2 disruptors are pan-cancer drugs to treat a wide range of solid tumors with innate or induced high replication stress.
Satya’s candidate-stage, first-in-class RAD51:BRCA2 inhibitor is an orally available small molecule compound with a biochemical potency of 2 nM, cellular potency of 20 nM, direct PD (RAD51 nuclear foci reduction) at 100 nM.
SAT-122 is clinically being positioned for PARPi-resistant ovarian and breast cancer patients, a high clinically unmet need. These patients have high RAD51 foci both as a biomarker and driver of resistance.
SAT-122 is designed to offer a potentially significantly better safety window compared to other HR pathway inhibitors including CHK 1/2 and ATR inhibitors
Satya Pharma Innovations
Flagship program - RAD51:BRCA2 Disruption
Potential foundational drug across all high replication stress tumors
RAD51 is the central recombinase involved in homologous-mediated DNA double strand break repair, downstream of PARP, ATR, ATM, and CHK1/2. The centrality and functionality of RAD51 in the DDR pathway confers upon it a broad role in various replication stress-induced cancers. Unlike precision oncology drugs, targeted RAD51:BRCA2 disruptors are pan-cancer drugs to treat a wide range of solid tumors with innate or induced high replication stress.
Satya’s candidate-stage, first-in-class RAD51:BRCA2 inhibitor is an orally available small molecule compound with a biochemical potency of 2 nM, cellular potency of 20 nM, direct PD (RAD51 nuclear foci reduction) at 100 nM.
SAT-122 is clinically being positioned for PARPi-resistant ovarian and breast cancer patients, a high clinically unmet need. These patients have high RAD51 foci both as a biomarker and driver of resistance.
SAT-122 is designed to offer a potentially significantly better safety window compared to other HR pathway inhibitors including CHK 1/2 and ATR inhibitors
Science
Satya is a pre-clinical stage targeted oncology company, building a portfolio of first-in-class and best-in-class therapeutics in the DDR space, in addition to other pathways/targets with potential pan-cancer applications.
We have pioneered targeting of RAD51:BRCA2 interactions as a druggable mechanism to treat a variety of high replication stress tumors.
Satya has a world-class scientific and executive team with a successful past track record of translating 75 research programs to over 15 clinical candidates across oncology and inflammatory disorders.
Science
Satya is a pre-clinical stage targeted oncology company, building a portfolio of first-in-class and best-in-class therapeutics in the DDR space, in addition to other pathways/targets with potential pan-cancer applications.
We have pioneered targeting of RAD51:BRCA2 interactions as a druggable mechanism to treat a variety of high replication stress tumors.
Satya has a world-class scientific and executive team with a successful past track record of translating 75 research programs to over 15 clinical candidates across oncology and inflammatory disorders.
TEAM
Leadership
Advisory Board
scientists, with preclinical and clinical expertise in oncology.
Pipeline
Targets focused on DDR pathway and Oncogenes.
TARGET
MOA / INDICATION
BIO MARKER
RIGHTS
EARLY DISCOVERY
LEAD OPTIMIZATION
PRE - CLINICAL
IND
RAD51:BRCA2 disruptor
DDR; PARPi-resistant Ovarian and Breast cancers
RAD51
Global
SOS1
Oncogene; NSCLC, CRC
EGFR mutation & Pan RAS mutation
Global
Undisclosed
DDR/ Cell cycle
Undisclosed
Partnered
Partnered with a Global Oncology Biotech
KIF18A
DDR; Solid tumors
CIN+ve cells
Global
PARG
(covalent inhibitor)
DDR; Breast and Ovarian cancers
HRD
Global
USP1
DDR; Breast and Ovarian cancers
HRD
Global
Pipeline
Targets focused on DDR pathway and Oncogenes.
TARGET
MOA / INDICATION
BIO MARKER
RIGHTS
EARLY DISCOVERY
LEAD OPTIMIZATION
PRE - CLINICAL
IND
RAD51:BRCA2 disruptor
DDR; PARPi-resistant Ovarian and Breast cancers
RAD51
Global
SOS1
Oncogene; NSCLC, CRC
EGFR mutation & Pan RAS mutation
Global
Undisclosed
DDR/ Cell cycle
Undisclosed
Partnered
Partnered with a Global Oncology Biotech
KIF18A
DDR; Solid tumors
CIN+ve cells
Global
PARG (Covalent inhibitor)
DDR; Breast and Ovarian cancers
HRD
Global
USP1
DDR; Breast and Ovarian cancers
HRD
Global
Pipeline
USP1 has been shown to deubiquitinate PCNA and FANCD2 in cells during Translesion synthesis (TLS) and intra-strand crosslink repair important for normal DNA damage response. Inhibition of USP1 causes ubiquitination of PCNA & FANCD2 leading to accummulation of damaged DNA leading to cell death
Recent highlights on our programs, News, Events and Leadership
Satya attending ASCO 2024 in Chicago (May 31st – June 4th, 2024)
Satya is attending ASCO in Chicago with a focus on DDR space. To set up
Satya to present preclinical profile of its PARG inhibitors at the 2024 American Association for Cancer Research (AACR) Annual Meeting – April 5-10, San Diego, CA
Abstract title Preclinical profile of novel and potent small molecule inhibitors of PARG Poster number 7112